Published 2 months ago • loading... • Updated 2 months ago

J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $132 per share, totaling about $14.6 billion, marking the largest biotechnology acquisition since early 2023.
The deal includes Intra-Cellular's drug Caplyta, approved for schizophrenia and bipolar depression, with potential for expanded use in major depressive disorder.
J&J CEO Joaquin Duato stated the acquisition supports the company's legacy in neuroscience and commitment to advancing care for neuropsychiatric disorders.
Analysts view the acquisition as a strategic move for J&J, providing opportunities in the neuroscience market despite recent drug failures by competitors.

Insights by Ground AI

Does this summary seem wrong?

53 Articles

All

Left

Center

Right

sherwood.news

Johnson & Johnson swallows another drugmaker in $14.6 billion deal

J&J has spent at least $56.5 billion on acquisitions in the past five years....

2 months ago

Read Full Article

Associated Press News

Reposted by

Yeshiva World News

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies.

2 months ago·United States

Read Full Article

abc News

J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

2 months ago·United States

Read Full Article

STAT

Pharmalittle: We're reading about J&J and GSK deals, a departing FDA official, and more

Patrizia Cavazzoni, who heads the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18

2 months ago·Boston, United States

Read Full Article

Investor's Business Daily

J&J Digs Deep In Neuropsych With A $14.6 Billion Acquisition

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies. The post Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal appeared first on Investor's Business Daily.

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports

Drug maker Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies , a biopharmaceutical company, Bloomberg News reported on Sunday, citing people familiar with the matter.

2 months ago·United Kingdom

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year